Table 4 No-ILD extra and no-extra groups clinical data and current pharmacological treatment
No—ILD ExtRA (n = 219) | No-ExtRA (n = 854) | P | |
|---|---|---|---|
Age [years, , mean ± SD] | 57.4 ± 10.1 | 55.4 ± 12.1 | 0.016 |
Sex (female) [n, %] | 196 (89.5%) | 764 (89.5%) | 0.988 |
RF positive [n, %] | 68 (82.9%) N = 82 | 659 (78.1%) N = 844 | 0.308 |
RF low titer < 3x [n,%] | 39 (23.1%) | 202 (30.7%) | 0.053 |
RF high titer ≥ 3x [n,%] | 130 (76.9%) | 457 (69.3%) | |
ACPA positivity | 55 (72.4%) N = 76 | 300 (78%) N = 383 | 0.257 |
Disease duration [years, mean ± SD] | 17.4 ± 10.7 | 13.7 ± 9.1 | < 0.001 |
Smoker, ever [n, %] | 94 (42.9%) | 330 (38.6%) | 0.248 |
Smoker, current [n, %] | 21 (9.6%) | 96 (11.2%) | 0.484 |
CDAI [mean ± SD] | 19.3 ± 16.4 | 11.5 ± 10.7 | < 0.001 |
DAS28-ESR [mean ± SD] | 4.37 ± 1.75 | 3.42 ± 1.41 | < 0.001 |
DAS28-CRP [mean ± SD] | 3.77 ± 1.67 | 3.17 ± 1.27 | < 0.001 |
HAQ-DI [mean ± SD] | 1.16 ± 0.86 | 0.88 ± 0.74 | < 0.001 |
ESR [mm, mean ± SD] | 35.2 ± 26.3 | 25.9 ± 23.3 | < 0.001 |
CRP [mg/L, mean ± SD] | 3.0 ± 7.3 | 1.6 ± 3.0 | < 0.001 |
Erosive disease [n,%] | 150 (69.8%) N = 215 | 420 (49.9%) N = 841 | < 0.001 |
scDMARD | |||
Methotrexate + Leflunomide | 35 (16.0%) | 142 (16.6%) | 0.818 |
Methotrexate | 149 (68%) | 572 (67%) | 0.766 |
Leflunomide | 61 (27.9%) | 301(35.2%) | 0.039 |
Antimalarials | 23 (10.5%) | 119 (13.9%) | 0.181 |
Sulfasalazine | 10 (4.6%) | 42 (4.9%) | 0.829 |
Azathioprine | 3 (1.4%) | 3 (0.4%) | 0.103 |
Cyclosporine | 1 (0.5%) | 2 (0.2%) | 0.496 |
DMARDts (tofacitinib) | 2 (0.9%) | 7 (0.8%) | > 0.999 |
Bdmard | |||
Anti-TNF | 52 (23.7%) | 159 (18.6%) | 0.089 |
Etanercept | 20 (9.1%) | 44 (5.2%) | 0.027 |
Certolizumab | 4 (1.8%) | 13 (1.5%) | 0.712 |
Golimumab | 8 (3.7%) | 28 (3.3%) | 0.784 |
Infliximab | 11 (5.0%) | 32 (3.7%) | 0.391 |
Adalimumab | 9 (4.1%) | 42 (4.9%) | 0.616 |
Non-anti TNF | 35 (16.0%) | 131 (15.3%) | 0.815 |
Abatacept | 12 (5.5%) | 57 (6.7%) | 0.520 |
Tocilizumab | 12 (5.5%) | 40 (4.7%) | 0.625 |
Rituximab | 11 (5.0%) | 34 (4%) | 0.493 |
Others | |||
NSAID | 32 (14.6%) | 63 (7.4%) | < 0.001 |
Glucocorticoids | 119 (54.3%) | 367 (43%) | 0.003 |